MDM4 and melanoma: The in vitro and in vivo induction of MDM4 exon 6 skipping using an antisense oligonucleotide have been reported to inhibit MDM4 protein abundance and melanoma growth and to increase sensitivity to MAPK-targeting therapeutics.